Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII

Vox Sanguinis

Volumn 86, Issue 2, 2004, Pages 92-99

  Foster, Peter R ^a   Griffin, B D ^a   Bienek, C ^a   McIntosh, R V ^a   MacGregor, I R ^a   Somerville, R A ^b   Steele, P J ^b   Reichl, H E ^c  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c Haemosan Life Science Services GmbH   (Austria)

Author keywords

Chromatography; Creutzfeldt Jakob disease; Factor VIII; Fibrinogen

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; FIBRINOGEN; LIBERATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; INFECTION RISK; ION EXCHANGE CHROMATOGRAPHY; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTIVITY;

ADSORPTION; ANIMALS; BIOLOGICAL ASSAY; BRAIN CHEMISTRY; CATTLE; CHROMATOGRAPHY, ION EXCHANGE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; ETHANOLAMINES; FACTOR VIII; FIBRINOGEN; HUMANS; MICE; MICE, INBRED STRAINS; MICROSOMES; POLYMERS; PRPSC PROTEINS; SENSITIVITY AND SPECIFICITY; SODIUM CHLORIDE; SODIUM HYDROXIDE; SOLVENTS; VIRULENCE;

EID: 1842576618     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0042-9007.2004.00403.x     Document Type: Article

References (42)

1. Will RG, Ironside JW, Zeilder M, Cousens SN, Estibeiro K, Alperovich A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921-925
2. Brown DA, Bruce ME, Fraser JR: Comparison of the neuropathological characteristics of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease in mice. Neuropathol Appl Neurobiol 2003; 29:262-272
3. Smith PG: The epidemic of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: current status and future prospects. Bull WHO 2003; 81:123-130
4. Wells GAH, Scott AC, Johnson CT, Gunning RF, Hancock RD, Jeffrey M, Bradley R: A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987; 121:419-420
5. Braakman JL: BSE in Europe. 9 July 2003: www.Bovine.nl
6. Preece MA: Creutzfeldt-Jakob disease: implications for growth hormone deficient children. Neuropathol Appl Neurobiol 1986; 12:509-515
7. Foster PR: Prions and blood products. Ann Med 2000; 32:501-513
8. Ironside JW, Head MW: Variant Creutzfeldt-Jakob disease and its transmission by blood. J Thromb Haemost 2003; 1:1479-1486
9. Buthem J, Roberts DJ: The pathophysiology of variant Creutzfeldt-Jakob disease: the hypothesis behind concerns for blood components and products. Br J Haematol 2003; 122:3-9
10. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, Al-Sarraj S, Ironside JW, Lantos PL, Collinge J: Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353:183-189
11. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F: Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83:267-271
12. Reid J: Developments in Variant CJD. House of Commons Statement by the Secretary of State for Health. House of Commons Hansard Debates for 17 December 2003 (Part 4): www.parliament.the-stationary-office.co.uk
13. Department of Health: Committee on Safety of Medicines Completes Review of Blood Products. London, UK Department of Health Press Release, May 13, 1998:98/182
14. Farrugia A: Risk of variant Creutzfeldt-Jakob disease from factor concentrates: current perspectives. Haemophilia 2002; 8:230-235
15. Ludlam CA: New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet 1997; 350:1740
16. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC: Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78:86-95
17. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN: The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38:810-816
18. Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JLC, Gilligan KJ, Rubenstein R, Fournel M, Petteway SR: Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000; 84:77-89
19. Lee DC, Stenland CJ, Miller JLC, Cai K, Fort EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR: A direct relationship between partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41:449-455
20. Vey M, Baron H, Weimer T, Gröner A: Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 2002; 30:187-196
21. Cai K, Miller JLC, Stenland CJ, Gilligan KJ, Hartwell RC, Tery JC, Evans-Storms R, Rubenstein R, Petteway SR, Lee DC: Solvent-dependent precipitation of prion protein. Biochim Biophys Acta 2002; 1597:28-35
22. Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC, Li H, Petteway S, Remington KM: Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003; 84:176-187
23. Van Holten RW, Autenreith SM: Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang 2003; 85:20-24
24. Reichl HE, Foster PR, Welch AG, Li Q, MacGregor IR, Somerville RA, Fernie K, Steele PJ, Taylor DM: Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang 2002; 83:137-145
25. Millson GC, Hunter GD, Kimberlin RH: An experimental examination of the scrapie agent in cell membrane mixtures. II. The association of scrapie activity with membrane fractions. J Comp Pathol 1971; 81:255-265
26. Dickinson AG, Meikle VM, Fraser H: Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968; 78:293-299
27. Bruce ME: Strain typing studies of scrapie and BSE; in Baker H, Ridley RM (eds): Methods in Molecular Medicine: Prion Diseases. Totowa, New Jersey, Humana Press, 1996:223-226
28. Dougherty R: Animal virus titration techniques; in Harris R (ed.): Techniques in Experimental Virology. London, Academic Press, 1964:169-223
29. Somerville RA, Carp RI: Altered scrapie infectivity estimates by titration and incubation period in the presence of detergents. J Gen Virol 1983; 64:2045-2050
30. Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, Jones R, DeArmond S: Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998; 38:817-820
31. Lee CA, Ironside JW, Bell JE, Giangrande P, Ludlam C, Esiri MM, McLaughlin JE: Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost 1998; 80:909-911
32. Clement P: Creutzfeldt-Jakob disease. Haemophilia 2000; 6:68-78
33. Evatt B: Creutzfeldt-Jakob disease and assessment of risk. Haemophilia 2000; 6:94-99
34. Cervenakova L, Brown P, Hammond DJ, Lee CA, Saenko EL: Factor VIII and transmissible spongiform encephalopathy: the case for safety. Haemophilia 2002; 8:63-75
35. Burnouf T: Chromatography in plasma fractionation: benefits and future trends. J Chromatogr B 1995; 664:3-15
36. Foster PR: Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999; 9:3-14
37. Blum M, Budnick MO, Chait EM, Vaz WE, MacAuley C, Rohwer RG: A bovine spongiform encephalopathy validation study for aprotinin and bovine serum albumin. Biopharma 1998; 11:28-34
38. Darling A: Validation of biopharmaceutical purification processes for virus clearance evaluation. Mol Biotechnol 2002; 21:57-83
39. Taylor DM: Inactivation of TSE agents: safety of blood and blood-derived products. Transfus Clin Biol 2003; 10:23-25
40. Sofer G: Current issues in the validation of chromatography; in Brown F, Lubiniecki AS (eds): Process Validation for Manufacturing of Biologics and Biotechnology Products. Developments in Biologicals, Vol. 113. Basel, Kager, 2002:61-64
41. Brown P, Cervenáková L, McShane LM, Barber P, Rubenstein R, Drohan WN: Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169-1178
42. Prowse CV, Bailey A: Validation of prion removal by leucocyte-depleting filters: a cautionary tale. Vox Sang 2000; 79:248